Antiplatelet and anticoagulant therapy

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Secondary prevention of ischemic stroke and transient ischemic attack (TIA) relies on antiplatelet therapy.
• Oral anticoagulants are established for stroke risk reduction in atrial fibrillation (AF).
• The optimal early management of acute ischemic stroke remains under investigation.

Purpose of the Study:

• To review the established role of antiplatelet therapy in secondary stroke prevention.
• To discuss oral anticoagulants and antiplatelet agents as alternatives in non-valvular atrial fibrillation.
• To highlight the ongoing research into antiplatelet and anticoagulant use during the acute phase of ischemic stroke.

Main Methods:

• Literature review of clinical guidelines and trial data.
• Analysis of evidence for antiplatelet and anticoagulant efficacy and safety.
• Synthesis of current understanding and future research directions.

Main Results:

• Antiplatelet therapy is a standard for secondary prevention post-TIA and ischemic stroke.
• In AF patients without stroke, oral anticoagulants reduce stroke risk; antiplatelet agents present a lower-risk option.
• The role of these therapies in acute ischemic stroke treatment is currently under evaluation in clinical trials.

Conclusions:

• Antiplatelet therapy is crucial for long-term secondary stroke prevention.
• Therapeutic choices in AF patients involve balancing stroke risk with bleeding risk, with antiplatelets as a potential alternative.
• Further research is essential to clarify the use of antiplatelet and anticoagulant therapies in the acute stroke setting.